Saturday 17 October 2026
Export ESTA’s income statement to Excel — free account
Establishment Labs Holdings Inc.
ESTA Healthcare Medical Devices
Establishment Labs Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $211.1 million, up 27.1% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 31.6%, free cash flow grew 2.75% and total debt rose 18.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
59.18
2.18
−3.55%
Follow ESTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 5 | 3 |
+8 more TTM periods Free account |
| (175.30%) | (164.01%) | (133.25%) | (338.19%) | ||
| (11.41%) | (12.78%) | (14.51%) | (26.70%) | ||
ROIC |
(5.53%) | (9.15%) | (12.47%) | (17.48%) | |
Return on Tangible Assets |
(15.12%) | (18.43%) | (20.98%) | (34.03%) | |
Average Days of Receivables |
112.33 | 122.54 | 134.01 | 136.54 | |
Free Cash Flow per Share |
(1.38) | (1.41) | (1.94) | (2.64) | |
Free Cash Flow |
(41.55) | (42.13) | (57.61) | (78.31) | |
Capital Expenditures |
(9.23) | (7.65) | (6.72) | (6.83) | |
| Other line items | |||||
Cash ROIC |
(11.72%) | (12.71%) | (16.62%) | (23.48%) | |
Accounts Receivable Turnover |
3.37 | 3.27 | 2.96 | 2.75 | |
Accounts Payable Turnover |
1.64 | 1.58 | 1.47 | 1.61 | |
Inventory Turnover |
0.81 | 0.78 | 0.79 | 0.77 | |
Average Days of Payables |
165.24 | 222.02 | 242.94 | 242.82 | |
Days of Inventory on Hand |
427.59 | 460.14 | 482.46 | 538.94 | |
Tax Rate |
(0.18) | (0.15) | (0.12) | 0.01 | |
Research and Development Expense of Revenue |
8.27% | 8.90% | 9.59% | 10.45% | |
Selling, General and Administrative Expense of Revenue |
69.85% | 73.60% | 78.20% | 86.43% | |
Share Based Compensation of Revenue |
4.97% | 5.39% | 5.60% | 6.53% | |
Interest Coverage |
(0.68) | (1.08) | (1.54) | (2.24) | |
Operating CF/Net income |
0.83 | 0.79 | 1.00 | 0.86 | |
Depreciation/Fixed assets |
0.14 | 0.14 | 0.14 | 0.13 | |
Capex/Depreciation |
(0.86) | (0.72) | (0.64) | (0.68) | |
Revenue per Share |
8.16 | 7.67 | 7.13 | 6.45 | |
Operating CF per Share |
(1.07) | (1.15) | (1.72) | (2.41) | |
Capex per Share |
(0.31) | (0.26) | (0.23) | (0.23) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.04 |
Columns are period end dates